In line with this reflection, Fudan University is evaluating zanubrutinib in combination with the immunochemotherapy R-CHOP in patients with non-GCB DLBCL with co-expression of MYC/BCL2, based on the findings of a posthoc analysis on four studies, in which an ORR of 61% and PFS of 5.4 months was achieved in patients with MYC and BCL2 overexpression treated with zanubrutinib (NCT05189197). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.